Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real Life Data for Otezla Evidence: Assessing Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France

NCT03757013 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03757013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03757013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real Life Data for Otezla Evidence: Assessing Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
Lead sponsor
Amgen
Phase
Observational
Overall status
Completed
Start date
September 25, 2018
Completion date
September 10, 2021
Enrollment
453 (actual)
Sites
93

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis